Provid Pharmaceuticals, Inc.

Monmouth Junction, NJ 08852

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $1.27MM
First Award Date 07/01/02
Most Recent Award Date 08/01/14

Key Personnel

Last Name Name Awards Contact
Self Christopher Raymond Self 1
Burke James R Burke 1
Olson Gary L Olson 5
Burns-Hamuro Lora L Burns-Hamuro 1
EL-DEIRY WAFIK S EL-DEIRY 1

8 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 08/01/14 - 07/31/15

Project Summary/Abstract TIC10 (ONC201) is a first-in-class antitumor agent and small molecule inducer of the TRAIL gene which was identified in a high-throughput small molecule library screen in the lab of our collaborator, Dr. Wafik El-Deiry at Penn State University and has been shown to have preclinical efficacy in several difficult-to-treat ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 05/01/10 - 10/31/11

DESCRIPTION (provided by applicant): The proposed research is directed toward the discovery of novel peptide inhibitors of platelet adhesion to the inflamed endothelium that would have value in the prevention and treatment of atherosclerosis, thrombosis, stroke, and heart attack. The novel mechanism addressed is inhibition of the F11 receptor (F...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/05 - 04/30/06

DESCRIPTION (provided by applicant): Celiac disease, also known as celiac sprue, is a inflammatory disease affecting the small intestine that results from an immunological reaction to dietary glutens. Celiac affects up to 1% of the population, and is managed only by a strict gluten-free diet. The disease is strongly associated with MHO class II...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/05 - 08/31/05

DESCRIPTION (provided by applicant): Cell permeable peptide inhibitors of protein kinase (PKA) sub-cellular localization will be designed to identify signal transduction pathways in cardiac myocytes that are specific for type I and type II isoforms of PKA. This will provide entry points for drug discovery efforts aimed at down-regulating specifi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/20/04 - 08/31/09

MS is an autoimmune disease affecting over 350,000 patients in the US in which the immune system attacks the myelin sheaths that insulate CNS axons, with secondary axonal damage contributing to long-term disability. The disease is associated with the major histocompatibility complex (MHC) class II molecule HLA- DR2 (DRA, DRB1*1501 ) that binds p...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/20/04 - 08/31/09

DESCRIPTION (provided by applicant): MS is an autoimmune disease affecting over 350,000 patients in the US in which the immune system attacks the myelin sheaths that insulate CNS axons, with secondary axonal damage contributing to long-term disability. The disease is associated with the major histocompatibility complex (MHC) class II molecule HL...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 04/15/04 - 03/31/05

DESCRIPTION (provided by applicant): Polyglutamine diseases are a group of inherited neurodegenerative diseases, including Huntington's disease, caused by abnormal expansions of the polyglutamine stretch to greater the 40 repeats in the disease protein. These diseases are characterized by selective neuronal degeneration causing motor control dy...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-AI-02-05
Budget: 07/01/02 - 06/30/03

DESCRIPTION (provided by applicant): This SBIR Phase I program will design and synthesize candidate inhibitors of bacterial RNA polymerases (RNAP) as an approach to the development of novel antibacterial agents for use in treatment of infectious diseases, including organisms such as B. anthracis and Y. pestis that are instruments of bioterrorism...